Team work, care paths can make a difference
As genetic testing and targeted therapies rapidly evolve, it can be difficult for the various parties involved in cancer care decision-making – clinicians, pathologists, administrators, insurers and regulators – to keep up with and agree on the appropriate diagnostic and treatment strategies.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
That can cause variability in the quality of care that individual cancer centers provide.
Cleveland Clinic oncologist Nathan Pennell, MD, PhD, discusses these challenges and ways to bring more coordination to the cancer care process in his recent ASCO Connection blog post.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust